Details

Autor(en) / Beteiligte

• Lambert, E
• Hollebosch, S
• van Praet, C
• Van Bruwaene, S
• Duck, L
• De Roock, W
• van Wambeke, S
• Ghysel, C
• Ameye, F
• Schatteman, P
• Vandenbroucke, F
• Sautois, B
• Baekelandt, F
• Ost, D
• Fransis, K
• Filleul, B
• Remondo, C
• Wynendaele, W
• Bamelis, B
• Logghe, P
• Vergauwe, E
• Denies, E
• Joniau, S
• Lumen, N

Titel

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis

Ist Teil von

• Acta clinica belgica (English ed. Online), 2022-11, Vol.77 (6), p.897-905

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2022

Beschreibungen/Notizen

• Abiraterone acetate + prednisone (AAP) and docetaxel have proven their efficacy in the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) in clinical trials. However, real-world data are scarce. The goal of this study is to evaluate real-world data on the efficacy and safety of these therapies in mHSPC patients. Records of 93 patients from 21 different centres were retrospectively reviewed. Primary and secondary endpoints were radiographic and PSA progression-free survival (RPFS - PSA-PFS) and cancer specific and overall survival (CSS - OS), respectively. Adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Differences in oncological outcome and AEs were evaluated between three treatment groups: ADT only (N=26) - ADT + AAP (N=48) - ADT + docetaxel (N=19). Survival analysis was performed using Kaplan-Meier statistics. Median RPFS was 13 months (95% confidence interval [CI]: 9-17) for ADT only, 21 months (95% CI: 19-23) for ADT + AAP and 12 months (95% CI: 11-14) for ADT + docetaxel (p = 0.004). The 1-year PSA-PFS, CSS and OS were 73.5%, 90.7% and 88.7%, respectively, with no significant differences between the three groups. Adverse events of grade 3 or higher were not observed more frequently. Retrospective real-world data show a significantly longer RPFS for mHSPC patients treated with ADT + AAP compared to ADT only or ADT + docetaxel at short-term follow-up. This can aid in counselling of mHSPC patients in daily clinical practice.